Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and carbamazepine dosing

Clinical Pharmacology and Therapeutics

Volumn 94, Issue 3, 2013, Pages 324-328

  Leckband, S G ^a,b   Kelsoe, J R ^a,b   Dunnenberger, H M ^c   George, A L ^d   Tran, E ^a   Berger, R ^a   Muller D J ^e,f   Whirl Carrillo, M ^g   Caudle, K E ^c   Pirmohamed, M ^h  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d VANDERBILT UNIVERSITY   (United States)

^e CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g STANFORD UNIVERSITY   (United States)

^h UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; HLA B ANTIGEN; ANTICONVULSIVE AGENT;

ALLELE; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HUMAN; PHARMACOGENETICS; PHENOTYPE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; COST BENEFIT ANALYSIS; ECONOMICS; GENETICS; RISK ASSESSMENT;

ANTICONVULSANTS; CARBAMAZEPINE; COST-BENEFIT ANALYSIS; GENETIC TESTING; GENETIC VARIATION; GENOTYPE; HLA-B ANTIGENS; HUMANS; RISK ASSESSMENT;

EID: 84883193885     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.103     Document Type: Review

References (39)

1. Martin, M.A., Klein, T.E., Dong, B.J., Pirmohamed, M., Haas, D.W. & Kroetz, D.L.; Clinical Pharmacogenetics Implementation Consortium. Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing. Clin. Pharmacol. Ther. 91, 734-738 (2012).
2. Shankarkumar, U., Shah, K.N. & Ghosh, K. Letter: HLA B*1502 allele association with oxcarbamazepine-induced skin reactions in epilepsy patient from India. Epilepsia 50, 1837-1838 (2009).
3. Lin, L.C., Lai, P.C., Yang, S.F. & Yang, R.C. Oxcarbazepine-induced Stevens-Johnson syndrome: a case report. Kaohsiung J. Med. Sci. 25, 82-86 (2009).
4. Chen, Y.C., Chu, C.Y. & Hsiao, C.H. Oxcarbazepine-induced Stevens-Johnson syndrome in a patient with HLA-B*1502 genotype. J. Eur. Acad. Dermatol. Venereol. 23, 702-703 (2009).
5. Locharernkul, C. et al. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia 49, 2087-2091 (2008).
6. He, N. et al. Cutaneous reactions induced by oxcarbazepine in Southern Han Chinese: incidence, features, risk factors and relation to HLA-B alleles. Seizure 21, 614-618 (2012).
7. Hu, F.Y., Wu, X.T., An, D.M., Yan, B., Stefan, H. & Zhou, D. Pilot association study of oxcarbazepine-induced mild cutaneous adverse reactions with HLA-B*1502 allele in Chinese Han population. Seizure 20, 160-162 (2011).
8. Hu, F.Y., Wu, X.T., An, D.M., Yan, B., Stefan, H. & Zhou, D. Phenytoin-induced Stevens-Johnson syndrome with negative HLA-B*1502 allele in mainland China: two cases. Seizure 20, 431-432 (2011).
9. Martin, A.M. et al. Predisposition to abacavir hypersensitivity conferred by HLA-B5701 and a haplotypic Hsp70-Hom variant. Proc. Natl. Acad. Sci. U.S.A. 101, 4180-4185 (2004).
10. Hung, S.I. et al. HLA-B5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc. Natl. Acad. Sci. U.S.A. 102, 4134-4139 (2005).
11. Hershfield, M.S. et al. Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. Clin. Pharmacol. Ther. 93, 153-158 (2013).
12. Pirmohamed, M. et al. Phenotype standardization for immune-mediated drug-induced skin injury. Clin. Pharmacol. Ther. 89, 896-901 (2011).
13. Yip, V.L., Marson, A.G., Jorgensen, A.L., Pirmohamed, M. & Alfirevic, A. HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review. Clin. Pharmacol. Ther. 92, 757-765 (2012).
14. Ozeki, T. et al. Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum. Mol. Genet. 20, 1034-1041 (2011).
15. McCormack, M. et al. HLA-A3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N. Engl. J. Med. 364, 1134-1143 (2011).
16. McLean, M.J. & Macdonald, R.L. Carbamazepine and 10,11- epoxycarbamazepine produce use-and voltage-dependent limitation of rapidly firing action potentials of mouse central neurons in cell culture. J. Pharmacol. Exp. Ther. 238, 727-738 (1986).
17. Warner, A., Privitera, M. & Bates, D. Standards of laboratory practice: antiepileptic drug monitoring. National Academy of Clinical Biochemistry. Clin. Chem. 44, 1085-1095 (1998).
18. Thorn, C.F. et al. PharmGKB summary: carbamazepine pathway. Pharmacogenet. Genomics 21, 906-910 (2011).
19. Hung, S.I. et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet. Genomics 16, 297-306 (2006).
20. Locharernkul, C., Shotelersuk, V. & Hirankarn, N. Pharmacogenetic screening of carbamazepine-induced severe cutaneous allergic reactions. J. Clin. Neurosci. 18, 1289-1294 (2011).
21. Roujeau, J.C. & Stern, R.S. Severe adverse cutaneous reactions to drugs. N. Engl. J. Med. 331, 1272-1285 (1994).
22. Nassif, A. et al. Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. J. Invest. Dermatol. 118, 728-733 (2002).
23. Nassif, A. et al. Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J. Allergy Clin. Immunol. 114, 1209-1215 (2004).
24. Naisbitt, D.J. et al. Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype, and cytokine profile of drugspecific T cell clones. Mol. Pharmacol. 63, 732-741 (2003).
25. Chung, W.H. et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 428, 486 (2004).
26. Man, C.B. et al. Association between HLA-B*1502 allele and antiepileptic druginduced cutaneous reactions in Han Chinese. Epilepsia 48, 1015-1018 (2007).
27. Ferrell, P.B. Jr & McLeod, H.L. Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics 9, 1543-1546 (2008).
28. Lonjou, C. et al.; RegiSCAR Group. A marker for Stevens-Johnson syndrome.: ethnicity matters. Pharmacogenomics J. 6, 265-268 (2006).
29. Tassaneeyakul, W. et al. Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population. Epilepsia 51, 926-930 (2010).
30. Mehta, T.Y. et al. Association of HLA-B*1502 allele and carbamazepineinduced Stevens-Johnson syndrome among Indians. Indian J. Dermatol. Venereol. Leprol. 75, 579-582 (2009).
31. Chang, C.C., Too, C.L., Murad, S. & Hussein, S.H. Association of HLA-B*1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in the multi-ethnic Malaysian population. Int. J. Dermatol. 50, 221-224 (2011).
32. Alfirevic, A., Jorgensen, A.L., Williamson, P.R., Chadwick, D.W., Park, B.K. & Pirmohamed, M. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics 7, 813-818 (2006).
33. Lonjou, C. et al.; RegiSCAR study group. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet. Genomics 18, 99-107 (2008).
34. Kaniwa, N. et al.; JSAR research group. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 9, 1617-1622 (2008).
35. Kim, S.H., Zeon, S.K., Choi, B.W., Kim, H.W., Won, K.S. & Kim, S.J. Usefulness of F-18 FDG PET/CT in the evaluation of neck swelling in polymorphic posttransplant lymphoproliferative disorder after renal transplantation. Clin. Nucl. Med. 36, 587-589 (2011).
36. Tennis, P. & Stern, R.S. Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study. Neurology 49, 542-546 (1997).
37. Roujeau, J.C. et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N. Engl. J. Med. 333, 1600-1607 (1995).
38. Chen, P. et al.; Taiwan SJS Consortium. Carbamazepine-induced toxic effects and HLA-B1502 screening in Taiwan. N. Engl. J. Med. 364, 1126-1133 (2011).
39. Hung, S.I. et al. Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics 11, 349-356 (2010).